Kelowna, British Columbia – TheNewswire – August 14, 2019 – Lexaria Bioscience Corp. , a global innovator in drug delivery platforms, is pleased to announce the appointment of Mr. Brian Quigley to its board of directors. Mr. Quigley most recently spent 16 years at Altria Group, with 7 of those years spent as President and Chief Executive Officer for U.S. Smokeless Tobacco and Nu-Mark, Altria’s innovation company, during the time that the existing business relationship between Altria and Lexaria was negotiated.
Mr. Quigley is a 20-yearConsumer Packaged Goods veteran of managing complex regulatory environments including for novel and innovative nicotine products, with additional deep experience with operations and marketing. In his time at Altria, Mr. Quigley spearheaded harm reduction strategies and worked to deliver results by creating change in the tobacco business in North America. Mr. Quigley has launched dozens of new products, created consumer-focused innovation strategies, and built businesses and cultures that deliver results.
Mr. Quigley formed Green Sky Strategy with other cannabis community leaders following four years of investing and strategic advisory roles to create the first cannabis strategy team that combines deep cannabis industry and consumer experience with proven Fortune 500 strategic thinking. A graduate of the University of New Hampshire, Mr. Quigley serves on the board of the Science Museum of Virginia Foundation and on the board of trustees of the Virginia Foundation for Independent Colleges.
“Lexaria continues to build towards its role as one of the world’s leading reduced harm nicotine delivery companies and we welcome Brian’s expertise,” said Chris Bunka, Chairman of the Board of Lexaria Bioscience Corp. “His years of regulatory, product launch, and Fortune-500 corporate experience will be an invaluable asset to Lexaria as we expand our presence in reduced-harm nicotine products around the world.”
“I am thrilled to be joining the already strong team at Lexaria Bioscience. From my first engagement with Chris, it was clear to me that Lexaria and its leadership team is positioned to create change through innovation in both the Cannabis and Nicotine space. It is an honor to join this team after forging such a strong partnership with them during my time with Altria.”
Lexaria Bioscience Corp. has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the USA and in Australia for utilization of its DehydraTECHTM delivery technology. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.
For regular updates, connect with Lexaria on Twitter (https://twitter.com/lexariacorp)
and on Facebook https://www.facebook.com/lexariabioscience/
FOR FURTHER INFORMATION PLEASE CONTACT:
Lexaria Bioscience Corp.
Alex Blanchard, Communications Manager
(250) 765-6424 ext. 202
This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements, including but not limited to: that any additional patent protection will be realized or that patent achievements will deliver material results. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process and other factors which may be identified from time to time in the Company’s public announcements and filings. There is no assurance that existing capital is sufficient for the Company’s needs or that it will be able to raise additional capital. There is no assurance the Company will be capable of developing, marketing, licensing, or selling edible products containing cannabinoids, nicotine or any other active ingredient. There is no assurance that any planned corporate activity, scientific research or study, business venture, letter of intent, technology licensing pursuit, patent application or allowance, consumer study, or any initiative will be pursued, or if pursued, will be successful. There is no assurance that any of Lexaria’s postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease.
英国哥伦比亚的 Kelowna —— TheNewswire ——2019年8月14日——全球药品交付平台创新者 Lexaria Bioscience Corp .高兴地宣布任命 Brian Quigley 先生为其董事会成员。奎格利最近在奥驰亚集团( Altria Group )工作了16年，其中7年担任美国无烟烟草公司( U.S . Smokless Tobacco )的总裁兼首席执行官，奥驰亚的创新公司 Nu-Mark 在奥驰亚与 Lexaria 现有业务关系谈判期间。
利盟生物科技公司( Lexiaria Bioscience Corp .)董事长克里斯•邦卡( Chris Bunka )表示：“利盟将继续发挥其作为全球领先的减少危害尼古丁输送企业之一的作用，我们欢迎布赖恩的专业知识。”财富500强企业的经验将是 Lexaria 的宝贵财富，因为我们将扩大我们在世界各地减少危害的尼古丁产品中的影响力。”
“我很高兴能加入 Lexaria Bioscience 已经很强大的团队。从我与 Chris 的第一次接触中，我清楚地看到， Lexaria 及其领导团队定位于通过 Cannabis 和 Nicotine 领域的创新来创造变革。在我与奥驰亚的合作中与他们建立了如此强大的合作关系，加入这个团队是一项荣誉。”
Lexiaria Bioscience Corp .开发并许可其颠覆性递送技术，该技术可促进更健康的摄入方法，降低整体剂量，提高亲脂性活性分子的有效性。Lexiaria 在全球40多个国家拥有多项专利，并在美国和澳大利亚获得了使用 DehydraTECTHTM 交付技术的专利。Lexaria 的技术为口服生物活性分子（包括大麻素、维生素、非甾体抗炎药（ NSAIDs ）、尼古丁和其他分子）提供了更高的肠道吸收率、更快的血液输送、以及重要的口服化益处。
如需定期更新，请在 Twitter 上与 Lexiaria 连接（ https://twitter.com/lexiaricorp ）
以及 Facebook 上的 https://www.facebook.com/levariabioscience/
Lexaria Bioscience 公司。
Alex Blanchard ，通信经理
本新闻稿包括前瞻性声明。非历史事实的陈述是前瞻性陈述。本公司就其预期未来财务状况、经营业绩、现金流量、融资计划、经营策略、产品及服务、竞争地位、增长机会、未来经营管理计划及目标作出前瞻性公开声明。包括“预期”、“如果”、“相信”、“计划”、“估计”、“预期”、“打算”、“可能”、“可以”、“应该”、“将”等词语在内的声明都是前瞻性声明，包括但不限于：将实现任何额外的专利保护或专利成就将带来重大成果。该等前瞻性陈述是反映本公司根据现时资料作出的最佳判断，并涉及多项风险及不明朗因素的估计，并不能保证其他因素不会影响该等前瞻性陈述的准确性。可能导致实际结果与本公司估计的结果存在重大差异的因素包括但不限于政府监管和监管审批、管理和保持增长、不利宣传、诉讼、竞争、科学发现的影响、专利申请和批准程序以及公司公告和备案文件中可能不时发现的其他因素。不能保证现有资本足以满足公司的需要或能够筹集额外资本。本公司不保证能够开发、营销、许可或销售含有大麻素、尼古丁或任何其他有效成分的食用产品。不能保证任何计划中的企业活动、科学研究或研究、商业风险、意向书、技术许可追求、专利申请或补贴、消费者研究或任何倡议都将被追求或如果被追求，将会成功。不能保证 Lexaria 的任何假设用途、利益或专利申请技术的优势事实上将以任何方式或任何部分实现。美国食品药品监督管理局（Food and Drug Administration）（ FDA ）尚未对此进行评估。利塞里亚尔相关产品不打算诊断、治疗、治愈或预防任何疾病。